Efficacy of intravesical Bacillus Calmette-Guérin therapy against tumor immune escape in an orthotopic model of bladder cancer

Huang,Peng; Ma,Chao; Xu,Peng; Guo,Kai; Xu,Abai; Liu,Chunxiao

doi:10.3892/etm.2014.2060

Efficacy of intravesical Bacillus Calmette-Guérin therapy against tumor immune escape in an orthotopic model of bladder cancer

Authors:
- Peng Huang
- Chao Ma
- Peng Xu
- Kai Guo
- Abai Xu
- Chunxiao Liu
View Affiliations

Affiliations: Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, P.R. China
Published online on: November 11, 2014 https://doi.org/10.3892/etm.2014.2060
Pages: 162-166

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to evaluate the antitumor immune response of the Bacillus Calmette‑Guérin (BCG) in an orthotopic bladder cancer model. The murine bladder cancer cell line MBT‑2 was transurethrally implanted in the bladder of syngeneic female C3H/He mice. The animals were randomly divided into three treatment groups: Phosphate‑buffered saline (PBS), low‑dose BCG and high‑dose BCG. The analyses of luciferin‑stained tumor images 28 days after each treatment showed significant tumor growth inhibition in the high‑dose group in comparison with that in the low‑dose‑ or PBS‑treated groups. In addition, the percentage of myeloid‑derived suppressor cells in the high‑dose group was significantly suppressed in comparison with that in the PBS and low‑dose agent treatment groups. These findings are notable in terms of the clinical evaluations of this therapy for patients with bladder cancer. The outcomes of this study also provide important implications regarding antitumor immune responses in human cancer.

View Figures

View References

1	DeSantis CE, Lin CC, Mariotto AB, et al: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Horinaga M, Fukuyama R, Iida M, et al: Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model. Urology. 76:1267e1–e6. 2010. View Article : Google Scholar : PubMed/NCBI
4	Burke J: Virustherapy for bladder cancer. Cytokine Growth Factor Rev. 21:99–102. 2010. View Article : Google Scholar : PubMed/NCBI
5	Jinesh GG and Kamat AM: Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination. Oncoimmunology. 1:1161–1162. 2012. View Article : Google Scholar
6	Askeland EJ, Newton MR, O’Donnell MA, et al: Bladder cancer immunotherapy: BCG and beyond. Adv Urol. 2012:1819872012. View Article : Google Scholar : PubMed/NCBI
7	Razack AH: Bacillus Calmette-Guerin and bladder cancer. Asian J Surg. 30:302–309. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ring S, Karakhanova S, Johnson T, et al: Gap junctions between regulatory T cells and dendritic cells prevent sensitization of CD8(+) T cells. J Allergy Clin Immunol. 125:237–246. 2010. View Article : Google Scholar : PubMed/NCBI
9	Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
10	Palucka K and Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277. 2012. View Article : Google Scholar : PubMed/NCBI
11	Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
12	Ro JY, Staerkel GA and Ayala AG: Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am. 19:435–453. 1992.PubMed/NCBI
13	Ping SY, Wu CL and Yu DS: Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway. Urol Oncol. 30:652–659. 2012. View Article : Google Scholar
14	Chan ES, Patel AR, Smith AK, et al: Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model. J Urol. 182:2926–2931. 2009. View Article : Google Scholar : PubMed/NCBI
15	Sica A and Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 117:1155–1166. 2007. View Article : Google Scholar : PubMed/NCBI
16	Ostrand-Rosenberg S and Sinha P: Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 182:4499–4506. 2009. View Article : Google Scholar : PubMed/NCBI
17	Gan C, Mostafid H, Khan MS and Lewis DJ: BCG immunotherapy for bladder cancer - the effects of substrain differences. Nat Rev Urol. 10:580–588. 2013. View Article : Google Scholar : PubMed/NCBI
18	Babjuk M, Burger M, Zigeuner R, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
19	Ehdaie B, Sylvester R and Herr HW: Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol. 64:579–585. 2013. View Article : Google Scholar : PubMed/NCBI
20	Zuiverloon TC, Nieuweboer AJ, Vékony H, et al: Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol. 61:128–145. 2012. View Article : Google Scholar
21	Zamarron BF and Chen W: Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 7:651–658. 2011. View Article : Google Scholar : PubMed/NCBI